Sample Size for Successful Genome-Wide Association Study of Major Depressive Disorder

被引:30
|
作者
Nishino, Jo [1 ,2 ]
Ochi, Hidenori [2 ,3 ,4 ]
Kochi, Yuta [2 ,5 ]
Tsunoda, Tatsuhiko [1 ,2 ,6 ,7 ]
Matsui, Shigeyuki [2 ,7 ,8 ]
机构
[1] Tokyo Med & Dent Univ, Med Res Inst, Dept Med Sci Math, Tokyo, Japan
[2] JST, CREST, Tokyo, Japan
[3] Hiroshima Univ, Dept Gastroenterol & Metab, Grad Sch Biomed Sci, Div Frontier Med Sci,Programs Biomed Res, Hiroshima, Japan
[4] RIKEN Ctr Integrat Med Sci, Lab Digest Dis, Hiroshima, Japan
[5] RIKEN Ctr Integrat Med Sci, Lab Autoimmune Dis, Yokohama, Kanagawa, Japan
[6] RIKEN Ctr Integrat Med Sci, Lab Med Sci Math, Yokohama, Kanagawa, Japan
[7] Inst Stat Math, Risk Anal Res Ctr, Tachikawa, Tokyo, Japan
[8] Nagoya Univ, Dept Biostat, Sch Med, Nagoya, Aichi, Japan
来源
FRONTIERS IN GENETICS | 2018年 / 9卷
关键词
major depressive disorder; genome-wide association studies (GWAS); semi-parametric hierarchical mixture model (SP-HMM); effect-size distribution; genome-wide significance; sample size; ANALYSIS IDENTIFIES 13; SUSCEPTIBILITY LOCI; GENETIC-LOCI; RISK LOCI; METAANALYSIS; DISEASE; SCHIZOPHRENIA; EPIDEMIOLOGY; ARCHITECTURE; POPULATIONS;
D O I
10.3389/fgene.2018.00227
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Major depressive disorder (MDD) is a complex, heritable psychiatric disorder. Advanced statistical genetics for genome-wide association studies (GWASs) have suggested that the heritability of MDD is largely explained by common single nucleotide polymorphisms (SNPs). However, until recently, there has been little success in identifying MDD-associated SNPs. Here, based on an empirical Bayes estimation of a semi-parametric hierarchical mixture model using summary statistics from GWASs, we show that MDD has a distinctive polygenic architecture consisting of a relatively small number of risk variants (similar to 17%), e.g., compared to schizophrenia (similar to 42%). In addition, these risk variants were estimated to have very small effects (genotypic odds ratio <= 1.04 under the additive model). Based on the estimated architecture, the required sample size for detecting significant SNPs in a future GWAS was predicted to be exceptionally large. It is noteworthy that the number of genome-wide significant MDD-associated SNPs would rapidly increase when collecting 50,000 or more MDD-cases (and the same number of controls); it can reach as much as 100 SNPs out of nearly independent (linkage disequilibrium pruned) 100,000 SNPs for similar to 120,000 MDD-cases.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Genome-wide association study of clinical course of major depressive disorder
    Myung, Woojae
    Kim, Jihye
    Lim, Shinn-Won
    Choi, Junbae
    Won, Hong-Hee
    Kim, Seonwoo
    Kim, Jong-Won
    Kim, Doh Kwan
    Kiwon, Kim
    [J]. INTERNATIONAL PSYCHOGERIATRICS, 2015, 27 : S119 - S120
  • [2] Genome-wide association study of clinical course of major depressive disorder
    Myung, Woojae
    Kim, Doh Kwan
    Kim, Jihye
    Lim, Shinn-Won
    Won, Hong-Hee
    Kim, Seonwoo
    Kim, Jong-Won
    Carroll, Bernard J.
    [J]. INTERNATIONAL PSYCHOGERIATRICS, 2013, 25 : S84 - S85
  • [3] Genome-wide Association Study of Duloxetine and Placebo Response in Major Depressive Disorder
    Mueller, Daniel J.
    Maciukiewicz, Malgorzata
    Marshe, Victoria S.
    Tiwari, Arun K.
    Fonseka, Trehani M.
    Freeman, Natalie
    Kennedy, James L.
    Rotzinger, Susan
    Foster, Jane A.
    Kennedy, Sidney H.
    [J]. BIOLOGICAL PSYCHIATRY, 2016, 79 (09) : 130S - 131S
  • [4] Genome-Wide Association Study of Duloxetine and Placebo Response in Major Depressive Disorder
    Marshe, Victoria S.
    Maciukiewicz, Malgorzata
    Tiwari, Arun K.
    Fonseka, Trehani M.
    Freeman, Natalie
    Rotzinger, Susan
    Foster, Jane A.
    Kennedy, James L.
    Kennedy, Sidney H.
    Mueller, Daniel J.
    [J]. GENETIC EPIDEMIOLOGY, 2016, 40 (07) : 652 - 652
  • [5] Enriched pathways for major depressive disorder identified from a genome-wide association study
    Kao, Chung-Feng
    Jia, Peilin
    Zhao, Zhongming
    Kuo, Po-Hsiu
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 (10): : 1401 - 1411
  • [6] Genome-Wide Association Study of Major Depressive Disorder in European Americans and African Americans
    Wen, Li
    Yao, Yinghao
    Payne, Thomas
    Ma, Jennie
    Li, Ming
    [J]. NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S362 - S362
  • [7] Genome-wide association study of recurrent early-onset major depressive disorder
    J Shi
    J B Potash
    J A Knowles
    M M Weissman
    W Coryell
    W A Scheftner
    W B Lawson
    J R DePaulo
    P V Gejman
    A R Sanders
    J K Johnson
    P Adams
    S Chaudhury
    D Jancic
    O Evgrafov
    A Zvinyatskovskiy
    N Ertman
    M Gladis
    K Neimanas
    M Goodell
    N Hale
    N Ney
    R Verma
    D Mirel
    P Holmans
    D F Levinson
    [J]. Molecular Psychiatry, 2011, 16 : 193 - 201
  • [8] A genome-wide association study of escitalopram treatment outcomes in patients with major depressive disorder
    Ren, Siyu
    Peng, He
    Zhang, Jinniu
    Yang, Jian
    He, Yi
    Sun, Zuoli
    Wang, Gang
    [J]. GENE, 2024, 926
  • [9] Genome-wide association study of recurrent early-onset major depressive disorder
    Shi, J.
    Potash, J. B.
    Knowles, J. A.
    Weissman, M. M.
    Coryell, W.
    Scheftner, W. A.
    Lawson, W. B.
    DePaulo, J. R., Jr.
    Gejman, P. V.
    Sanders, A. R.
    Johnson, J. K.
    Adams, P.
    Chaudhury, S.
    Jancic, D.
    Evgrafov, O.
    Zvinyatskovskiy, A.
    Ertman, N.
    Gladis, M.
    Neimanas, K.
    Goodell, M.
    Hale, N.
    Ney, N.
    Verma, R.
    Mirel, D.
    Holmans, P.
    Levinson, D. F.
    [J]. MOLECULAR PSYCHIATRY, 2011, 16 (02) : 193 - 201
  • [10] Genome-wide association studies of placebo and duloxetine response in major depressive disorder
    Maciukiewicz, M.
    Marshe, V. S.
    Tiwari, A. K.
    Fonseka, T. M.
    Freeman, N.
    Kennedy, J. L.
    Rotzinger, S.
    Foster, J. A.
    Kennedy, S. H.
    Mueller, D. J.
    [J]. PHARMACOGENOMICS JOURNAL, 2018, 18 (03): : 406 - 412